Why the Synlait (SM1) share price is falling today

The Synlait Milk Ltd (ASX: SM1) share price is trading lower today following the release of a manufacturing supply agreement.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Synlait Milk Ltd (ASX: SM1) share price is trading lower today following the release of a manufacturing supply agreement.

At the time of writing, shares in the dairy processing company are down 2.44% to $4.80.

Let's take a closer look and see what new deal Synlait signed.

What does Synlait do?

Synlait is a dairy processing company based in Canterbury, New Zealand. The company manufactures and sells ingredients and nutritional milk powders for infants, as well as specialised products for adults.

Synlait works with more than 200 milk suppliers that are located no further than 80km away from the manufacturing plant. This ensures consistent fresh milk that can cater to ongoing demand. Every hour, more than 9 tonnes of infant milk can be processed at its state-of-the-art facilities, which are said to be the largest in the southern hemisphere.

New agreement

According to the release, Synlait signed a manufacturing supply agreement with an established, global category leader. The company did not specify which strategic partner it took on board due to confidentiality terms.

Under the agreement, Synlait will manufacture, blend, and package nutrition products which include plant-based products. This will allow utilisation of its manufacturing chain to deliver consumer products to the market.

Synlait's Pokeno and Auckland's capacity are expected to be customised for processing and packaging. Capital expenditure is estimated to be around $70 million, which will be spread over two years. Commercial production is currently slated to begin in mid-2022.

The agreement will have a positive impact on earnings in FY23.

What did the CEO say?

Commenting on the new deal, Synlait CEO Leon Clement said:

This is the start of a valuable, enduring, strategic partnership that gives us broader market and category exposure in Asia Pacific.

Asian markets are experiencing strong sector growth as consumers seek nutritional products that support better health. Synlait is excited to play a role in this journey. This is a significant step forward for us as we genuinely diversify our customer, category and geographic reach.

Synlait share price summary

The dairy processor's shares have been on a steady decline from April, falling from $7.25 to $4.83. This reflects a 33% loss. Earlier, the Synlait share price dipped to a multi-year low of $4.33 in March due to the impact of COVID-19, and is only slightly up since then.

The company has a market capitalisation of $883.5 million and a price-to-earnings ratio (P/E) of 17.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Share Market News

Forget Westpac shares, these ASX ETFs could be better buys

Here's why these funds could be quality picks for investors looking for alternatives to the banks.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors.

Read more »

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »